Frontiers in Endocrinology · 2022 · 11 citations · 19 references
MedicinePharmacologyPharmacotherapyBone MetabolismClinical PharmacologyMolecular PharmacologyAngiogenesisBone HealthBone Metabolism DisordersBone Metabolism PharmacotherapyOsteoporosisOsteoporosis PharmacotherapyBone AngiogenesisBone Resorption InhibitionGlucocorticoid-induced Bone LossGlucocorticoid-induced Osteoporosis TherapyGlucocorticoid-induced Osteoporosis TreatmentHypoxia-inducible Factor SignalingRenin-angiotensin-aldosterone System ActivationVascular Endothelial Growth Factor
Objective: To explore whether the modified Qing' e Pills (MQEP) exerts anti-osteoporotic effects and prevents bone loss by enhancing angiogenesis. Methods: Network pharmacology was used to assess whether MQEP has a pro-angiogenic capacity and to predict its potential targets. Human umbilical vein endothelial cells were treated with glucocorticoids and MQEP to assess cell viability. The expression of angiotensin II type 1 receptor, angiotensin II type 2 receptor, and angiotensin converting enzyme, which are associated with the activation of the renin-angiotensin-aldosterone system, and the expression of vascular endothelial growth factor and hypoxia-inducible factor 1 alpha, which are associated with the formation of type H blood vessels, were examined by western blot and RT-qPCR. Thereafter, the glucocorticoid-induced osteoporosis model was established and intervened with MQEP. Femur scanning was performed with micro-computed tomography; trabecular spacing, trabecular thickness, and trabecular number were observed and calculated; the expression of nuclear factor-kappa B ligand and osteoprotegerin was detected by ELISA, and the ratio was calculated to evaluate the degree of bone resorption. Finally, type H blood vessels that were highly coupled to osteogenic cells were identified by immunohistochemistry staining and flow cytometry. Results: experiments confirmed that MQEP could effectively promote the proliferation of vascular endothelial cells and alleviate glucocorticoids-induced activation of the renin-angiotensin-aldosterone system, thereby reducing vascular injury. Conclusion: MQEP exerts anti-osteoporosis effects and prevents bone loss by alleviating vascular injury caused by renin-angiotensin-aldosterone system activation and promoting type H blood vessel formation.
19
PDGF-BB secreted by preosteoclasts induces angiogenesis during coupling with osteogenesis
Hui Xie, Zhuang Cui, Long Wang et al. · Nature Medicine · 2014 · 944 citations · Full text
Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption
Michelle M. McDonald, Weng Hua Khoo, Pei Ying Ng et al. · Cell · 2021 · 413 citations · Full text
Targeting skeletal endothelium to ameliorate bone loss
Ren Xu, Alisha R. Yallowitz, An Qin et al. · Nature Medicine · 2018 · 370 citations
Human type H vessels are a sensitive biomarker of bone mass
Liang Wang, Fei Zhou, Peng Zhang et al. · Cell Death and Disease · 2017 · 158 citations · Full text
Medicine, Endocrinology, Aging +16